Merck enlists Avanir to sell Januvia products; Lundbeck rolls out new ONFI formulations;

@FiercePharma: Twist for Perrigo's Elan buy, per Leerink Swann: Perrigo must maintain Irish headcount to keep key tax breaks. So cost-cutting ability limited. | Follow @FiercePharma

@CarlyHFierce: Regeneron puts $70M in plant expansion amid growing Eylea demand. More from FiercePharmaManufacturing | Follow @CarlyHFierce

> Merck ($MRK) tapped Avanir Pharmaceuticals ($AVNR) to copromote its Januvia and Janumet drugs to long-term care facilities. Report

> Lundbeck said new formulations of its ONFI seizure drug have hit the market in the U.S. Report

> India's Wockhardt may soon get encouraging news from FDA about transferring production from its troubled Waluj plant to other facilities, allowing it to resume exporting to the U.S., Indian media reports. Report

> Houston-based Pernix Therapeutics plans to sell $30 million worth of generic assets to Boca Raton, FL, drugmaker Breckenridge Pharmaceutical. Report

Medical Device News

@FierceMedDev: Trending on FierceMedicalDevices: Medtronic bags telehealth biz for $200M. More | Follow @FierceMedDev

@DamianFierce: GenMark wants to turn the page on June's plunge with a $60M stock sale. Story | Follow @DamianFierce

@MichaelGFierce: Receptor-targeted antifolate drugs yield fewer side effects. More from FierceDrugDelivery | Follow @MichaelGFierce

@MarkHFierce: Modest growth ahead for the U.S. spinal implant market. Article | Follow @MarkHFierce

> Endo ships out urology unit as device sales lurch. News

> Given wins FDA nod for next-gen PillCam device. More

> Baxter wins Chinese OK for $4B Gambro buyout. Story

> Rexam solicits buyers for healthcare packaging arm in potential $1 billion deal. Article

Biotech News

@FierceBiotech: ICYMI: Biotechs crowd list of top growth leaders as Big Pharmas shrink staffs. Feature | Follow @FierceBiotech

@JohnCFierce: If the OS results for necitumumab were more than very, very slim, I'll be surprised. | Follow @JohnCFierce

@RyanMFierce: Why not. Langer's Bind files $80M IPO as new biotech offerings go gangbusters. Story | Follow @RyanMFierce

> GlaxoSmithKline JV wins FDA OK on HIV blockbuster dolutegravir. Report

> Bristol-Myers buries another depression drug after PhII flops. Story

> Biotech accelerator BioMotiv gets a $20M commitment from new investor. Article

Pharma Manufacturing News

@EricPFierce: India's Aurobindo Pharma expanding its sterile injectables capacity at newest facility. More from FiercePharma.com | Follow @EricPFierce

> Russia's Pharmstandard to buy Singapore API maker. News

> Compounder recalls drugs that may have caused infections. Item

> Mylan geared up for big expansion in India. More

> Manufacturing issues trip up Novo on new therapy. Article

> India's Aurobindo buys, boosts sterile capacity. Story

Biotech Research News

@EmilyMFierce: U.K. nonprofits offering funding for novel Parkinson's targets. More from FierceBiotechResearch.com | Follow @EmilyMFierce

> NIH to open genomic data of HeLa cells to researchers. Story

> Newly discovered proteins could play role in destroying cancer cells. Article

> Stem cell combo therapy extends survival of mice with brain tumors. More

> University of Maryland, Baltimore partners with 5 biotech companies. Item

And Finally... Eliminating co-pays on essential drugs really can improve compliance. Report

Suggested Articles

WuXi AppTec has appointed Celgene CAR-T program veteran David Chang to lead its cell and gene therapy CDMO, WuXi Advanced Therapies.

Maryland-based Emergent BioSolutions has won a $628 million contract with BARDA to manufacture targeted COVID-19 vaccine hopefuls.

About 76% remdesivir patients had at least one point of clinical improvement on a 7-point scale at day 11, versus 66% of patients on standard care.